Posters

Aflibercept as first line therapy for neovascular type age-related macular degeneration: A real-life study

Poster Details

First Author: S.Kadayifcilar TURKEY

Co Author(s):    O. Inam   S. Kadayifcilar                          

Abstract Details



Purpose:

To report the early anatomic and visual results of aflibercept monotherapy for naive neovascular age related macular degeneration (nARMD).

Setting:

University Hospital Ophthalmology Department

Methods:

Forty-one eyes of 35 patients treated with intravitreal aflibercept for nARMD were enrolled in this retrospective study. Baseline and monthly follow-up exams included visual acuity (VA) measurement with ETDRS charts, fundus exam and spectral domain optical coherence tomography (OCT) with Heidelberg Spectralis while fluorescein angiography was performed at the beginning and when necessary. Patients were followed monthly and aflibercept was applied as PRN.

Results:

The mean age of the patients was 75.56±7.86 (53-91). A mean of 5.10±2.96 (1-11) aflibercept injections were performed in 14.61±5.12 (6-24) months. At baseline exam BCVA was 50.98±19.65 letters, central macular thickness (CMT) 392.51±99.83 microns on OCT and greatest linear dimension (GLD) of the lesion on FFA was 2135±1177.85 microns. Intraretinal fluid (IRF) was present in 56.1%, subretinal fluid (SRF) in 75.6%, pigment epithelial detachment (PED) in 92.7%, subretinal haemorrhage in 24.4%, geographic atrophy (GA) in 32.4%, and epiretinal membrane in 25.6% of eyes. Mean BCVA in letters was 57.06±16.75 at month 1, 57.94±16.07 at month 3, 57.44±15.2 at month 6, 58.93±18.59 at month 9 and 59.93±20.7 at month 12. CMT in microns was 315.6±73.48 at month 1, 316.76±72.28 at month 3, 324.32±89.91 at month 6, 313.91±65.57 at month 9, and 301.21±62.27 at month 12. This decrease was found to be significant (p=0.001). SRF decreased significantly at all visits when compared to baseline. The BCVA increased more than 15 letters in 10 eyes (24.4%) and decreased more than 15 letters in 5 eyes (12.2%) at the last visit. No ocular or systemic side effect was encountered.

Conclusions:

Aflibercept for naive nARMD stabilized vision and improved anatomy in this short term real life study.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy